Document peG39Q9DkqVJyw1KmDYQ15o2B

f porporate Toxicology and Regulatory Services 3rv, e lUilding 0220-02-E-02 St. Pain,-!*, 55144-1000 651 733 1773 Fax k Certified Mail October 4, 2004 Document Processing Center EPA East - Room 6428 Attn: Section 8(e) Office of Pollution Prevention and Toxics US EPA 1200 Pennsylvania Avenue NW Washington DC 20460-0001 m RE: TSCA 8 (e) SUPPLEMENTAL SUBMISSION: Docket No. 8EHQ-1180-373, 374 x Dear Docket Coordinators: On December 4, 2002, 3M provided EPA with preliminary results from repeated dermal contact absorption/toxicology study in rats conducted with four mill-applied and aftermarket carpet/fabric/upholstery protector products that 3M ceased manufacturing as part of its perfluorooctanyl chemistries phase out. The preliminary results indicated that three compounds, believed to be derived from manufacturing residuals of the protector products, were observed in some of the liver and serum samples analyzed post exposure to those products. The three compounds are: 1) PFOS - perfluorooctanesulfonate ; 2) PFHS perfluorohexanesulfonate; and 3) M-570 - N-methyl-perfluorooctanesulfonamide. The final report for this study contains results that are consistent with the previously reported information. Enclosed please find the following final report and appendices on CD: 28-Day Repeated Dermal Contact in Rats (8 test materials); Dated 08-16-04 T-7088 liquid / T-7338 liquid dried on gauze - FX 1860 T-7092 liquid / T-7339 liquid dried on gauze - FX 3539 T-7340 liquid / T-7341 liquid dried on gauze - FC 1395 T-7342 liquid / T-7343 liquid dried on gauze - FC-288 Note: Reference page 9 of the final report for detail regarding test materials Appendix A-D - Sample Re-analysis, Clinical Observation, Body Weight, Liver Weight Appendix E - Histopathological findings Appendix F - PFOS in liver samples Appendix G - Amendments and Deviations Appendix H - Exygen Data (Analytical) ^ gg cr> rv> > c3 Please contact John Butenhoff (651-733-1962) if you have any questions or if we can provi8t? additional information. Larry R. Johnson Director, Corporate Toxicology and Regulatory Services Enclosure 89050000008 6 050